Difference between revisions of "Part:BBa K321004"

(→‎Function)
 
(2 intermediate revisions by one other user not shown)
Line 10: Line 10:
  
 
===Function===
 
===Function===
−
This part was shown to inhibit the activation of killer cells by the UCSF 2010 team.  We used this part in our ANDN gate to increase the precision of killing toward cancer cells.  The figure below shows that this part performs its inhibitory function as expected: it inhibits killer cell activation in the presence of antigen B, which is recognized by the extracellular domain of the synthetic receptor bearing the part (red and striped bars).  For more information please see our <html><a href="http://2010.igem.org/Team:UCSF/Project/Precision#andn">wiki</a></html>.
+
This part was shown to inhibit the activation of killer cells by the UCSF 2010 team.  We used this part in our ANDN gate to increase the precision of killing toward cancer cells.  The figure below shows that this part performs its inhibitory function as expected.  On the X-axis are different types of target cells, which represent normal and cancer cells expressing different combinations of surface antigents in our experiment.  The Y-axis shows the activation levels of killer cells engineered to express synthetic receptors, one of which bears this part as its intracellular domain.  The data show that in the presence of antigen B, which is recognized by the synthetic receptor bearing this part, killer cell activation is inhibited
 +
(red and striped bars) regardless of the presence of activating antigen A.  For more information please see our <html><a href="http://2010.igem.org/Team:UCSF/Project/Precision#andn">wiki</a></html>.
  
 
<br>
 
<br>
Line 23: Line 24:
 
<partinfo>BBa_K321004 SequenceAndFeatures</partinfo>
 
<partinfo>BBa_K321004 SequenceAndFeatures</partinfo>
  
 +
==References==
 +
 +
Brewerton DA, Hart FD, Nicholls A, Caffrey M, James DC, Sturrock RD. Ankylosing spondylitis and HL‐A 27. Lancet 1973; 1: 904– 7.
 +
Crossref CAS PubMed Web of Science®Google Scholar
 +
 +
Brown MA. Breakthroughs in genetic studies of ankylosing spondylitis. Rheumatology (Oxford) 2008; 47: 132– 7.
 +
Crossref CAS PubMed Web of Science®Google Scholar
 +
 +
Gonzalez‐Roces S, Alvarez MV, Gonzalez S, Dieye A, Makni H, Woodfield DG, et al. HLA‐B27 polymorphism and worldwide susceptibility to ankylosing spondylitis. Tissue Antigens 1997; 49: 116– 23.
  
 
<!-- Uncomment this to enable Functional Parameter display  
 
<!-- Uncomment this to enable Functional Parameter display  

Latest revision as of 18:33, 20 October 2020

intracellular chain of KIR3DL1

Encodes the intracellular signaling chain of the KIR3DL1 immune receptor. Inhibits immune cell activation via the ITIM (immunoreceptor tyrosine-based inhibition motif) motif.


Usage and Biology

In immune Natural Killer cells, Killer cell immunoglobulin-like receptors (KIRs) inhibit cell mediated cytotoxicity upon ligand binding. In their intracellular domains, these receptors possess immune tyrosine-based inhibitory (ITIM) motifs that when phosphorylated recruit phosphotases that decrease the activation molecules involved in immune cell signaling.

Function

This part was shown to inhibit the activation of killer cells by the UCSF 2010 team. We used this part in our ANDN gate to increase the precision of killing toward cancer cells. The figure below shows that this part performs its inhibitory function as expected. On the X-axis are different types of target cells, which represent normal and cancer cells expressing different combinations of surface antigents in our experiment. The Y-axis shows the activation levels of killer cells engineered to express synthetic receptors, one of which bears this part as its intracellular domain. The data show that in the presence of antigen B, which is recognized by the synthetic receptor bearing this part, killer cell activation is inhibited (red and striped bars) regardless of the presence of activating antigen A. For more information please see our wiki.




Sequence and Features


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    COMPATIBLE WITH RFC[1000]

References

Brewerton DA, Hart FD, Nicholls A, Caffrey M, James DC, Sturrock RD. Ankylosing spondylitis and HL‐A 27. Lancet 1973; 1: 904– 7. Crossref CAS PubMed Web of Science®Google Scholar

Brown MA. Breakthroughs in genetic studies of ankylosing spondylitis. Rheumatology (Oxford) 2008; 47: 132– 7. Crossref CAS PubMed Web of Science®Google Scholar

Gonzalez‐Roces S, Alvarez MV, Gonzalez S, Dieye A, Makni H, Woodfield DG, et al. HLA‐B27 polymorphism and worldwide susceptibility to ankylosing spondylitis. Tissue Antigens 1997; 49: 116– 23.